Koers BioMerieux SA Xetra
Aandelen
EYW
FR0010096479
Medische apparatuur, benodigdheden & distributie
Omzet 2024 * | 3,9 mld. 4,17 mld. | Omzet 2025 * | 4,19 mld. 4,48 mld. | Marktkapitalisatie | 10,83 mld. 11,58 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 465 mln. 497 mln. | Nettowinst (verlies) 2025 * | 527 mln. 563 mln. | EV/omzet 2024 * | 2,74 x |
Nettoliquiditeiten 2024 * | 153 mln. 164 mln. | Nettoliquiditeiten 2025 * | 400 mln. 428 mln. | EV/omzet 2025 * | 2,49 x |
K/w-verhouding 2024 * |
23,8
x | K/w-verhouding 2025 * |
21
x | Werknemers | - |
Dividendrendement 2024 * |
0,97% | Dividendrendement 2025 * |
1,13% | Vrij verhandelbaar | 36,23% |
Recentste transcriptie over BioMerieux SA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 01-11-16 |
Chairman | 50 | 16-04-04 | |
Director of Finance/CFO | 47 | 01-03-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 74 | 15-09-06 | |
Director/Board Member | 63 | 01-01-05 | |
Chairman | 50 | 16-04-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-12,79% | 7,33 mld. | |
+26,65% | 5,68 mld. | |
-17,87% | 3,71 mld. | |
+7,41% | 2,49 mld. | |
-65,15% | 2,35 mld. | |
+28,63% | 2,23 mld. | |
-11,56% | 2,22 mld. | |
-14,32% | 1,61 mld. | |
-9,41% | 1,36 mld. |